Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Up 8.3 %

Shares of NASDAQ:AKTX opened at $1.31 on Friday. The company has a 50 day moving average of $1.53 and a 200-day moving average of $2.66. Akari Therapeutics has a one year low of $0.90 and a one year high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.